NCT04744116 2025-11-10
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Recruiting
Clinical Trials
14 trialsNCT06904131 2025-04-01
A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors
Obstetrics & Gynecology Hospital of Fudan University
Phase NA Recruiting
NCT06158139 2025-03-18
Autologous CAR-T Cells Targeting B7-H3 in PDAC
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT06849921 2025-02-27
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
Ruijin Hospital
Phase NA Active not recruiting
NCT03691376 2024-09-19
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT06196294 2024-06-26
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
Phase 1 Recruiting
NCT03240861 2023-11-01
NYESO SCT
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05312476 2022-04-05
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02814864 2021-08-03
PRISME
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01947322 2017-08-29
NK
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Completed
NCT00149019 2011-04-08
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Hadassah Medical Organization
Phase 2 Withdrawn
NCT00149006 2007-03-14
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
Hadassah Medical Organization
Phase 2 Unknown